Review
doi: 10.1016/j.medcli.2013.04.008.
Epub 2013 Jun 27.
[The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm]
[Article in
Spanish]
Affiliations
- PMID: 23809407
- DOI: 10.1016/j.medcli.2013.04.008
Item in Clipboard
Review
[The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm]
[Article in
Spanish]
Med Clin (Barc).
.
No abstract available
Similar articles
-
Update on HER-kinase-directed therapy in prostate cancer.Clin Adv Hematol Oncol. 2004 Jan;2(1):53-6, 64. Clin Adv Hematol Oncol. 2004. PMID: 16163160 Review.
-
Ten years of HER2-directed therapy: still questions after all these years.Breast Cancer Res Treat. 2009 Jan;113(2):207-9. doi: 10.1007/s10549-008-0041-2. Epub 2008 May 8. Breast Cancer Res Treat. 2009. PMID: 18463974 No abstract available.
-
[Breast cancer and Her-2].Nihon Rinsho. 2007 Jun 28;65 Suppl 6:87-94. Nihon Rinsho. 2007. PMID: 17682144 Review. Japanese. No abstract available.
-
Anti-epidermal growth factor receptor strategies for advanced breast cancer.Cancer Invest. 2008 Oct;26(8):757-68. doi: 10.1080/07357900801971040. Cancer Invest. 2008. PMID: 18853311 Review. No abstract available.
-
[The potential of monoclonal antibodies in cancer : established trastuzumab and cetuximab and promising targets IGF-1R and c-MET].Med Sci (Paris). 2009 Dec;25(12):1090-8. doi: 10.1051/medsci/200925121090. Med Sci (Paris). 2009. PMID: 20035684 Review. French.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
